585 related articles for article (PubMed ID: 22350410)
1. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.
Mulholland DJ; Kobayashi N; Ruscetti M; Zhi A; Tran LM; Huang J; Gleave M; Wu H
Cancer Res; 2012 Apr; 72(7):1878-89. PubMed ID: 22350410
[TBL] [Abstract][Full Text] [Related]
2. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.
Jefferies MT; Cox AC; Shorning BY; Meniel V; Griffiths D; Kynaston HG; Smalley MJ; Clarke AR
J Pathol; 2017 Dec; 243(4):442-456. PubMed ID: 29134654
[TBL] [Abstract][Full Text] [Related]
3. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
Kinross KM; Brown DV; Kleinschmidt M; Jackson S; Christensen J; Cullinane C; Hicks RJ; Johnstone RW; McArthur GA
Mol Cancer Ther; 2011 Aug; 10(8):1440-9. PubMed ID: 21632463
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
Ruscetti M; Dadashian EL; Guo W; Quach B; Mulholland DJ; Park JW; Tran LM; Kobayashi N; Bianchi-Frias D; Xing Y; Nelson PS; Wu H
Oncogene; 2016 Jul; 35(29):3781-95. PubMed ID: 26640144
[TBL] [Abstract][Full Text] [Related]
5. PTEN loss-mediated Akt activation increases the properties of cancer stem-like cell populations in prostate cancer.
Kim RJ; Bae E; Hong YK; Hong JY; Kim NK; Ahn HJ; Oh JJ; Park DS
Oncology; 2014; 87(5):270-9. PubMed ID: 25139413
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.
Abou-Kheir WG; Hynes PG; Martin PL; Pierce R; Kelly K
Stem Cells; 2010 Dec; 28(12):2129-40. PubMed ID: 20936707
[TBL] [Abstract][Full Text] [Related]
7. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
8. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
Chappell WH; Steelman LS; Long JM; Kempf RC; Abrams SL; Franklin RA; Bäsecke J; Stivala F; Donia M; Fagone P; Malaponte G; Mazzarino MC; Nicoletti F; Libra M; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Milella M; Tafuri A; Bonati A; Evangelisti C; Cocco L; Martelli AM; McCubrey JA
Oncotarget; 2011 Mar; 2(3):135-64. PubMed ID: 21411864
[TBL] [Abstract][Full Text] [Related]
9. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
10. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways.
Gu J; Tamura M; Yamada KM
J Cell Biol; 1998 Nov; 143(5):1375-83. PubMed ID: 9832564
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.
Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
Cell Death Dis; 2013 Oct; 4(10):e875. PubMed ID: 24157869
[TBL] [Abstract][Full Text] [Related]
13. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract][Full Text] [Related]
14. Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression.
Patel R; Gao M; Ahmad I; Fleming J; Singh LB; Rai TS; McKie AB; Seywright M; Barnetson RJ; Edwards J; Sansom OJ; Leung HY
J Clin Invest; 2013 Mar; 123(3):1157-75. PubMed ID: 23434594
[TBL] [Abstract][Full Text] [Related]
15. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
16. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.
Martin P; Liu YN; Pierce R; Abou-Kheir W; Casey O; Seng V; Camacho D; Simpson RM; Kelly K
Am J Pathol; 2011 Jul; 179(1):422-35. PubMed ID: 21703421
[TBL] [Abstract][Full Text] [Related]
17. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
18. Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice.
Liu J; Muturi HT; Khuder SS; Helal RA; Ghadieh HE; Ramakrishnan SK; Kaw MK; Lester SG; Al-Khudhair A; Conran PB; Chin KV; Gatto-Weis C; Najjar SM
Metabolism; 2020 Jun; 107():154215. PubMed ID: 32209360
[TBL] [Abstract][Full Text] [Related]
19. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
20. Eupafolin suppresses prostate cancer by targeting phosphatidylinositol 3-kinase-mediated Akt signaling.
Liu K; Park C; Chen H; Hwang J; Thimmegowda NR; Bae EY; Lee KW; Kim HG; Liu H; Soung NK; Peng C; Jang JH; Kim KE; Ahn JS; Bode AM; Dong Z; Kim BY; Dong Z
Mol Carcinog; 2015 Sep; 54(9):751-60. PubMed ID: 24700667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
